Cronos Group Inc. (NASDAQ: CRON) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 18.72 | EPS (ttm) | 0.18 | Insider Own | 7.17% | Shs Outstand | 373.66M | Perf Week | 6.65% |
| Market Cap | 1.26B | Forward P/E | 29.74 | EPS next Y | 0.11 | Insider Trans | 0.00% | Shs Float | 192.24M | Perf Month | 4.98% |
| Enterprise Value | 463.24M | PEG | 9.70 | EPS next Q | 0.03 | Inst Own | - | Short Float | 1.69% | Perf Quarter | 26.22% |
| Income | 70.00M | P/S | 5.18 | EPS this Y | -12.50% | Inst Trans | - | Short Ratio | 2.66 | Perf Half Y | 32.68% |
| Sales | 243.00M | P/B | 1.13 | EPS next Y | -28.04% | ROA | 5.91% | Short Interest | 3.24M | Perf YTD | 28.14% |
| Book/sh | 2.99 | P/C | 1.58 | EPS next 5Y | 1.93% | ROE | 6.46% | 52W High | 3.61 -6.65% | Perf Year | 30.12% |
| Cash/sh | 2.13 | P/FCF | 23.42 | EPS past 3/5Y | - | ROIC | 0.05% | 52W Low | 2.28 47.81% | Perf 3Y | 49.78% |
| Dividend Est. | - | EV/EBITDA | 19.30 | Sales past 3/5Y | 19.64% 25.96% | Gross Margin | 45.37% | Volatility | 3.38% 3.29% | Perf 5Y | -45.73% |
| Dividend TTM | - | EV/Sales | 1.91 | EPS Y/Y TTM | 63.64% | Oper. Margin | 0.30% | ATR (14) | 0.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 15.25 | Sales Y/Y TTM | 105.93% | Profit Margin | 38.95% | RSI (14) | 60.92 | Recom | 3.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16.18 | EPS Q/Q | 190.00% | SMA20 | 2.07% | Beta | 0.89 | Target Price | 3.15 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | 115.15% | SMA50 | 9.92% | Rel Volume | 0.64 | Prev Close | 3.29 |
| Employees | 610 | LT Debt/Eq | 0.00 | Earnings | Nov 05 | SMA200 | 21.87% | Avg Volume | 1.15M | Price | 3.37 |
| IPO Date | Feb 27, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 800.00% 19.93% | Net Debt/EBITDA | -8.60 | Volume | 741,616 | Change | 2.43% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jan-14-26 | Reiterated | Bernstein | Perform | $2.30 |
| Aug-09-24 | Reiterated | Bank of America Securities | Buy | $2.30 |
| Sep-30-22 | Reiterated | Barclays | Equal Weight | $3.50 |
| May-11-22 | Reiterated | Canaccord Genuity | Sell | $4.50 |
| Mar-22-22 | Upgrade | Barclays | Underweight → Equal Weight | |
| Jan-27-22 | Upgrade | Jefferies | Underperform → Hold | |
| Apr-14-20 | Downgrade | Piper Sandler | Overweight → Neutral | |
| Mar-31-20 | Downgrade | Canaccord Genuity | Hold → Sell | |
| Aug-09-19 | Upgrade | Canaccord Genuity | Sell → Hold | |
| Jun-05-19 | Upgrade | B of A Securities | Underperform → Buy |
Cronos Group Inc. is a company primarily focused on cannabinoids. In the United States, it develops, promotes, and supplies hemp-derived wellness and beauty products under the Lord Jones and Happy Dance brands, reaching consumers through online sales, traditional retail outlets, and partnerships within the hospitality sector. Beyond hemp, the company also engages in the cultivation, production, and commercialization of cannabis and its related extracts for both therapeutic and recreational consumption. Its cannabis offerings encompass dried flower, pre-rolled joints, edibles, concentrates, and various extracts, which are distributed via wholesale channels and directly to clients. The wellness segment operates under the PEACE NATURALS platform, while its adult-use products are marketed through the Spinach brand. Additionally, Cronos exports dried cannabis and cannabis oils to international markets such as Germany, Israel, and Australia. Founded in 2012, the company's headquarters are located in Toronto, Canada.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 243 | 149 | 118 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 161 | 87 | 92 | — | — | — | — | — | — | |
| Gross Profit | 80 | 62 | 25 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 66 | 64 | 77 | — | — | — | — | — | — | |
| Research and Development | 4 | 4 | 4 | — | — | — | — | — | — | |
| Other Operating Expense | -1 | 12 | 21 | — | — | — | — | — | — | |
| Operating Income | 12 | -18 | -77 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 56 | 0 | 113 | — | — | — | — | — | — | |
| Net Income Before Taxes | 69 | -17 | 37 | — | — | — | — | — | — | |
| Income Taxes | -11 | -14 | -3 | — | — | — | — | — | — | |
| Consolidated Net Income | 70 | -10 | 41 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 79 | -3 | 40 | — | — | — | — | — | — | |
| Net Income | 70 | -10 | 41 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.18 | -0.03 | 0.11 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.18 | -0.03 | 0.11 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.18 | -0.03 | 0.11 | — | — | — | — | — | — | |
| EBITDA | 24 | -3 | -50 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 18.72 | — | 18.36 | — | — | — | — | — | — | |
| Price To Sales Ratio | 5.34 | 6.80 | 6.54 | — | — | — | — | — | — | |
| Gross Margin | 32.92 | 41.61 | 21.19 | — | — | — | — | — | — | |
| Operating Margin | 4.94 | -12.08 | -65.25 | — | — | — | — | — | — | |
| Net Margin | 28.81 | -6.71 | 34.75 | — | — | — | — | — | — | |
| Shares Outstanding | 385 | 385 | 382 | — | — | — | — | — | — | |
| Market Capitalization | 1,297 | 1,013 | 772 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Wagner Adam | See remarks | May 12 '26 | Option Exercise | 0.00 | 10,367 | 0 | 103,987 | May 14 |
| Buggy Shannon | See Remarks | May 12 '26 | Option Exercise | 0.00 | 20,622 | 0 | 187,501 | May 14 |
| Kenost Jared Matthew | See Remarks | May 12 '26 | Option Exercise | 0.00 | 9,412 | 0 | 46,675 | May 14 |
| Doucet Terrence Gregory Joseph | See Remarks | May 12 '26 | Option Exercise | 0.00 | 10,597 | 0 | 115,787 | May 14 |
| Kenost Jared Matthew | See Remarks | May 10 '26 | Option Exercise | 0.00 | 12,649 | 0 | 39,141 | May 12 |
| Weigensberg Arye | See Remarks | May 10 '26 | Option Exercise | 0.00 | 3,118 | 0 | 211,555 | May 12 |
| Wagner Adam | See remarks | May 10 '26 | Option Exercise | 0.00 | 20,470 | 0 | 93,620 | May 12 |
| Shlimak Anna | See Remarks | Mar 19 '26 | Option Exercise | 0.00 | 28,429 | 0 | 368,362 | Mar 20 |
| Weigensberg Arye | See Remarks | Mar 15 '26 | Option Exercise | 0.00 | 24,236 | 0 | 208,437 | Mar 17 |
| GORENSTEIN MICHAEL RYAN | See remarks below | Mar 15 '26 | Option Exercise | 0.00 | 324,540 | 0 | 13,340,723 | Mar 17 |
| Shlimak Anna | See Remarks | Mar 15 '26 | Option Exercise | 0.00 | 45,226 | 0 | 356,287 | Mar 17 |
| JACOBSON JEFFREY DAVID | Chief Growth Officer | Mar 15 '26 | Option Exercise | 0.00 | 59,191 | 0 | 507,233 | Mar 17 |
| Buggy Shannon | See Remarks | Mar 15 '26 | Option Exercise | 0.00 | 20,938 | 0 | 176,081 | Mar 17 |
| Doucet Terrence Gregory Joseph | See Remarks | Mar 15 '26 | Option Exercise | 0.00 | 23,897 | 0 | 117,466 | Mar 17 |
| Wagner Adam | See remarks | Mar 12 '26 | Option Exercise | 0.00 | 15,715 | 0 | 73,150 | Mar 16 |